CA2989161C - Ethynylxanthines, preparation and use for cancer treatment - Google Patents

Ethynylxanthines, preparation and use for cancer treatment Download PDF

Info

Publication number
CA2989161C
CA2989161C CA2989161A CA2989161A CA2989161C CA 2989161 C CA2989161 C CA 2989161C CA 2989161 A CA2989161 A CA 2989161A CA 2989161 A CA2989161 A CA 2989161A CA 2989161 C CA2989161 C CA 2989161C
Authority
CA
Canada
Prior art keywords
4alkyl
purine
3alkyl
amino
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989161A
Other languages
French (fr)
Other versions
CA2989161A1 (en
Inventor
Pavels Arsenjans
Jelena VASILJEVA
Ilona Domracheva
Irina Shestakova
Anita GULBE
Iveta KANEPE-LAPSA
Valerjans Kauss
Ivars Kalvins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latvian Institute of Organic Synthesis
Original Assignee
Latvian Institute of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvian Institute of Organic Synthesis filed Critical Latvian Institute of Organic Synthesis
Publication of CA2989161A1 publication Critical patent/CA2989161A1/en
Application granted granted Critical
Publication of CA2989161C publication Critical patent/CA2989161C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to ethynylxanthine derivatives of formula (l) which exhibit high antiproliferative activity against various tumour cell lines, methods for their synthesis and use for the treatment and/or prevention of cancer.

Description

ETHYNYLXANTHINES, PREPARATION AND USE FOR CANCER
TREATMENT
FIELD OF THE INVENTION
The present invention relates to novel ethynylxanthine derivatives, methods for their synthesis and use for the treatment and/or prevention of cancer.
BACKGROUND OF THE INVENTION
Cancer is one of the main causes of death among economically developed countries (Jermal, CA Cancer J. Clin., 2011, 61 69-90). According to the International Health Organization, more than 7 million people diagnosed with various forms of cancer, die each year (Jermal, CA Cancer J. Clin., 2010, 60, 277-300; Siegel, CA Cancer J.
Clin.
2012, 62, 10-29). Unfortunately, the number of cancer diagnosis in past few years has increased almost twice. In clinical practice, the treatment of cancer involves a wide range of chemotherapy drugs. Besides, most of them exhibit various side effects, high toxicity and moderate selectivity. Therefore, a new generation of selective, low toxic anticancer agent development is one of the main tasks in medicinal chemistry and pharmaceutical industries. Despite the advanced studies in the elaboration of anticancer drugs, the treatment outcome for brain malignant tumors still remains a challenge. The majority of promising antitumor drugs used against brain tumors in clinical trials, unfortunately, had limited impact on human survival, due to inadequacy of efficient drug delivery to the target in the central nervous system (CNS) at a sufficient concentration (Siegal, Neuro Oncol., 2013 10.1093/neuonc/not016;
Lampson, Drug Discov. Today, 2009, 14, 185-191; Huse, Nat. Rev., 2010, 10, 319-331).
Increased interest in xanthines stems from the fact that this heterocyclic system occurs in a number of natural substances; xanthine derivatives are able to cross through the blood brain barrier (BBB). It is an important class of compounds with a wide range of pharmacological effects, including anticancer, anti-HIV, anticoagulant, antispasmodic and antibacterial activity. Nowadays, in clinical practice, a number of anticancer drugs based on the structure of the natural purine analogues were developed (cladribine, fludarabine, mercaptopurine, thioguanine, clofarabine, nelarabine, etc.).
These are the first line therapy agents to cure hematologic malignant diseases. Agents Date Recue/Date Received 2021-07-07
2 in the therapeutic effect of complete remission constitute 80% after monochemotherapy course. Such compounds act as antimetabolites by replacing the natural nucleoside in DNA and RNA synthesis such as multi-cellular enzyme inhibitors. Unfortunately, these drugs showed a wide range of side effects, and high treatment costs limit the possibilities in clinical practice.
To minimize side effects currently being developed antitumor drugs based on caffeine core. Caffeine derivatives possess CNS expression as calcium agonist or antagonist effect. Recent studies show that caffeine-containing coffee daily use is able to lower mouth and brain cancer formation up to 39% (Michaud, Am. J. Clin. Nutr. 2010, 92, 1145-50; Kang, Cancer. Res. 2010, 70, 1173-83). Also, it reduces the risk of women cervical cancer development. Caffeine reduces a chance of prostate cancer formation in men by 60%. The same effect was observed in ability to prevent breast, colon and hepatic cancer (Hepatology, 2007, 46, 430-435). Caffeine enhances doxorubicin, cisplatin activity in metastatic carcinomas, lymphomas, bone and soft tissue sarcomas (Hayashi, Anticancer Res., 2005, 25, 2399-2406). Also, caffeine effectively inhibits breast cancer resistance protein (BCRP) multidrug resistance (MDR) on MCF-7 and MCF-7/MX100 (mitoxantrone-resistant) cell lines. One of the advantages of caffeine derivatives action is the ability to cross through the BBB. It opens the possibility to cure malignant diseases, such as neuroblastoma and glioblastoma multiforme, in the brain (Vartanyan, Psychopharm. Biol. Narc., 2005, 5, 1093-1095). Drugs used in neuro-oncology (temodar, carmustine (BCNU), lomusthine (CCNU), etc.) have a limited ability to cross through the BBB and are highly toxic. In a series of caffeine analogues, such as 8-(3-(dimethylamino)propoxy)caffeine (proxyfeine), antitumor agents were developed, however introduction in the clinic of the EU
and the US interferes, due to high levels of toxicity (LD50=355 mg/kg), as well as a large number of serious side effects. Proxyfeine (RU 2166948, 20.05.2001) is used in chemotherapy for cancer patients at high risk of brain metastases and the rehabilitation of the metastatic lesions to the brain, as well as the early stages of cancer metastasis prevention in Russia and other countries.

/ \
N
ONN
Date Recue/Date Received 2021-07-07
3 Proxyfeine PCT Patent application No. W02008077557 discloses preparation of 8-ethynyl xanthine derivatives as selective A2A receptor antagonists and their use as medicines, for example, in the treatment of dopamine-related movement disorders, _________________________________________________ R3 ON N

8-Ethynyl xanthines wherein RI and R2 represent, e.g., hydrogen, C1_6alkyl, cycloalkyl, heterocycloalkyl, aryl (wherein these groups may be further substituted), etc.; R3 represents e.g., aryl, hetaryl group.
PCT Patent application No. W02014/143799 A2, 2014 discloses preparation of N7-benzyl 8-ethynyl xanthine derivatives as agents for treatment of short transient receptor potential channel 5 (TrpC5) disorders A2A receptor antagonists and their use as medicines, for example, in the treatment of dopamine-related movement disorders.

m (Ra)r, R3, N
¨R2 ONN

N-Benzy1-8-ethynyl xanthines THE PRESENT INVENTION
We have discovered that certain ethynylxanthine derivatives exhibit high antiproliferative activity against various tumor cell lines. Therefore, these substances may be therapeutically beneficial in the treatment of tumors. These substances may be administered in the form of a pharmaceutical composition, wherein they are present together with one or more pharmaceutically acceptable diluents, carriers, or excipients.
OBJECTS OF THE INVENTION
It is an object of the present invention to provide novel antiproliferative compounds, methods for their synthesis and use for treatment and/or prevention cancer.
Date Recue/Date Received 2021-07-07
4 SUMMARY OF THE INVENTION
What we therefore believe to be comprised by our invention may be summarized inter alia in the following words:
A compound selected from those of Formula I

Nz = _____________________________________________ R4 1, IR' wherein RI represents hydrogen, C1_4alkyl, hydroxy-C2_4alkyl, C1_3alkoxy-C2_4a1kyl, CI-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(C1_3alkyl)amino-C2_4alkyl;
R2 represents C1_4alkyl, hydroxy-C2_4alkyl, C1_4alkylcarbonyl-C1_4alkyl, C1_3alkoxy-C2-4a1ky1, C1_3alkyl(C1_3alkyl)amino-C2_4alkyl or halo-C2_4a1ky1;
R3 represents CI4alkyl, allyl or C1_3a1k0xy-C2_4a1ky1;
R4 represents C1_4alkyl, hydroxy-C1_4alkyl, Ci_3a1koxy-C1_4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(C1-3alkyl)methyl, 1-amino-di-(C13alkyl)methyl, 1-hydroxy-cyclo-C3-6a1ky1, 1-amino-cyclo-C3_6a1ky1, 1 -(hy droxy-C1_3alkyl)-cy cloC3_6a1ky1, Ci-3a1ky1amin0-C1-3alkyl, C1_3alkyl(C1_3alkyl)amino-C1_3alkyl, di-(Ci_3alkoxy-C2_4alkyl)-amino-C1_3alkyl, heterocyclyl-C13alkyl, aryl or heteroaryl;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
Date Recue/Date Received 2021-07-07
5 wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocyclyl may be azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C1_4alkoxycarbonyl; N-C1_ 4alkylaminocarbonyl, N,N-di-(C1-3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI-4alkyl, allyl, C2_4alkynyl, C1_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alkoxy, hydroxy-Ci_4alkyl, Ci_3alkoxy-Ci_4alkyl, Ci_3alkoxy-C2_4alkoxy, di-(C1-3alkyl)amino, di-(C1_3alkyl)amino-C1_3alkyl, di-(C1_3a1kyl)amino-C2_4alkoxy, C1_4alkylsulfonylamino and Ci_4alkyl-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1-4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6a1k0xy, C1_3a1k0xy-C1_4a1ky1, cyclo-C3_6a1ky1amin0 and di -(C i_3alkyl)amino;
its optical isomers, and pharmaceutically acceptable acid addition salts and hydrates and solvates thereof In some embodiments, R4 represents hydroxy-C1_4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(C1_3alkyl)methyl, 1-amino-di-(C1-3alkyl)methyl, 1-hydroxy-cyclo-C3-6a1ky1, amino-cyclo-C3_6alkyl, 1 -(hydroxy-C1_3alkyl)-cycloC3_6alkyl, C1_3alkyl(C1_ 3alkyl)amino-C1_3alkyl, di-(C1-3alkoxy-C2_4alkyl)-amino-C1_3alkyl, heterocyclyl-Ci-3a1ky1 or aryl.
In some embodiments, R2 and R3 each independently represent C1_4alkyl or CI_ 3alkoxy-C2_4alkyl with the proviso that if R2 is ethyl, R3 is methyl and R4 is hydroxy-ethyl, then RI is not a hydrogen.
Date Recue/Date Received 2021-07-07
6 In some embodiments, R2 and R3 each represent methyl.
In some embodiments, R1 represents methyl or 5-oxohexyl.
Specific compounds of Formula I within the present invention include but are not limited to:
8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexypethyny1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione, 8-(3-(bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3 ,7-Trimethy1-8-(3-(pip eridin-1 -y 1)prop-1-yn-1 -y1)-1H-purine-2,6(3H,7H)-di one, 8-(3-(Azepan-1-yl)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-Hy droxy -3 -methylbut-l-yn-1 -y1)-3,7-dimethy1-1 -(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexypethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-(3-(Bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1 -y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione, 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,9H)-dione, 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione Date Recue/Date Received 2021-07-07
7 and optical isomers, polymorphs, and pharmaceutically-acceptable acid addition salts, hydrates, and solvates thereof The invention also relates to a manufacturing process of a compound selected from those of Formula! as defined above, comprising reaction of a compound of Formula ' ONN

II
wherein RI, R2 and R3 are as defined for Formula I above, with a compound of Formula!!!:
¨ ____________________________________ R4 III
wherein R4 is as defined for Formula! above, optionally in the presence of base in an appropriate solvent (e.g., DIEA in DMF, NMP, DMAC or Et0Ac), in the presence of CuI and palladium catalyst generated in situ (e.g., from PdC12 or Pd(OAc)2 and PPh3) or commercially available (Ph3P)4Pd to yield a compound of Formula!, which may be converted, if desired, into an optical isomer, polymorph, pharmaceutically-acceptable salt, hydrate or solvate.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "C1_4alkyl" represents straight or branched chain alkyl groups having 1, 2, 3 or 4 carbon atoms, examples of such alkyl groups include methyl, ethyl, n-propyl, 2-propyl, n-butyl, 2-butyl, iso-butyl and tert-butyl.
The term "cyclo-C3_6alkyl" represents monocyclic alkyl groups having 3, 4, 5 or 6 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
Date Recue/Date Received 2021-07-07
8 The term "heterocycly1" represents a saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, examples of such heterocyclyl groups include azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl.
The term "halo" or "halogen" represents fluorine, chlorine, bromine and iodine.
In addition, using methods known to those skilled in the art, analogs and derivatives of the compounds of the invention can be created which have improved therapeutic efficacy, i.e., higher potency and/or selectivity at a specific targeted receptor type, greater ability to penetrate mammalian blood-brain barriers, fewer side effects, etc.
It will be appreciated by those skilled in the art that compounds of the invention having a chiral center may exist in and be isolated in optically active and racemic forms. It is to be understood that the present invention encompasses any racemic, optically-active, tautomeric, or stereoisomeric form of a compound of the invention, which possesses the useful properties described herein.
For therapeutic use, the compounds of Formula I can be in the form of a pharmaceutically acceptable salt or a solvate. The term "pharmaceutically acceptable"
refers here to the therapeutically active non-toxic salt forms, which the compounds of Formula I are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids such as hydrochloric acid, hydrobromic acid; sulfuric acid; nitric acid; phosphoric acid and the like; or organic acids such as acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, oxopropanoic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, methanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, 2-hydroxybenzoic, and like acids.
Conversely, the salt may be converted to the free base by treatment with alkali.
Scheme 1 describes the preparation of compounds of Formula I of the present invention. All of the starting materials II are prepared by representative procedures described in Schemes 2 and 3, by procedures well known to one of ordinary skill in organic chemistry or can be obtained commercially. All of the final compounds of the present invention are prepared by procedures described in these charts or by Date Recue/Date Received 2021-07-07
9 procedures analogous thereto, which procedures would be well known to one of ordinary skill in organic chemistry. All of the variables used in the schemes are as defined below or as in the claims.
We have found that product yields in palladium catalyzed cross-coupling of terminal acetylenes and 8-bromoxanthines strongly depends on the nature of catalyst and solvent. In accordance with experimental data, reaction of terminal acetylenes III with 8-bromoxanthines under routine experimental conditions (Methods A and B) in general led to the formation of the corresponding 8-ethynylxanthines I in very low yields. Suprisingly, we have found that use of the mixture of N-methylpyrrolidine and toluene (1:1) (Method C) gave the desired products in high yields. Alternative method was elaborated (Method D). Performing the reaction in ethyl acetate and using 2 mol-% of Pd(PPh3)4 and 2 mol-% of PdC12 decreases the cost of reaction. It should be noted that in the representative example the treatment of 8-bromocaffeine with two equivalents of 2-methylbut-3-yn-2-ol under conditions of Method D led to the formation of desired 8-(3-hy droxy-3-methy lbut-1 -yn-1 -y1)-1,3 ,7-trimethy1-1H-purine-2,6(3H,7H)-dione (I-1) in 55% yield and by-product 8-RE)-5-hydroxy-2-(1-hydroxy-1 -methylethyl)-5 -methylhex-1 -en-3-ynyl] -1,3 ,7-trimethy1-1H-purine-2,6(3H,7H)-dione in 26% yield similar to the method elaborated previously (Arsenyan, Tetrahedron Left., 2013, 54, 6524-6528).
Scheme 1. General procedure toward compounds of Formula I.

R1'N R1 R3 Br + I R4 'N V __ R4 ONN ONN
F'R2 II III I
Reaction conditions:
Method A. (Ph3P)2PdC12, CuI, N-methylpyrrolidine or DMF, DIEA, 50 C;
Method B. Pd(OAc)2, Ph3P, CuI, N-methylpyrrolidine or DMAC, DIEA, 55 C;
Method C. Pd(OAc)2, Ph3P, CuI, N-methylpyrrolidine/toluene (1:1), DIEA, 50 C;

Method D. Pd(PPh3)4, PdC12, Ph3P, Cul, ethyl acetate, DIEA, 40 C.
Date Recue/Date Received 2021-07-07
10 Compounds II, wherein R3 is at purine N(7), can be prepared by bromination of position 8 of corresponding 8-unsubstituted 1,3,7-substituted 1H-purine-2,6(3H,7H)-diones. Representative method for the synthesis of compound II wherein R1 and are methyl groups shown in Scheme 2. Commercially available caffeine (1) and pentoxifylline (2) are brominated in position 8 by N-bromosuccinimide (NBS) in dichloromethane in analogy to published procedure [Synlett, 2012, 23, 1191-1198].
Both products 3 and 4 were isolated in almost quantitative yields.
Scheme 2. General procedure for the preparation of 8-bromo 1H-purine-2,6(3H,7H)-diones II, wherein R3 is at purine N(7) (3, 4).

N NBSN N
I I
C) N N ONN

I (RI = Me) 3 (RI = Me) 2 (RI = MeC(0)(CH2)4) 4 (RI = MeC(0)(CH2)4) Compounds II, wherein R3 is at purine N(9), can be prepared by bromination of position 8 of respective 8-unsubstituted 1,3,9-substituted 1H-purine-2,6(3H,9H)-diones. Representative method for the synthesis of compound II wherein RI, R2 and R3 are methyl groups (compound 11) is shown in Scheme 3. Thus, 1,3-dimethy1-6-chlorouracil (6) was prepared by the treatment of 1,3-dimethylbarbituric acid (5) in phosphorous oxychloride (P0C13) with water followed by heating under reflux.
Then treatment of compound 6 with a mixture of fuming nitric acid and sulfuric acid resulted in formation of 6-chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7). Next, choro substituent was substituted by methylamino moiety to give intermediate 8 and nitro group was reducted by hydrogen using palladium on charcoal as a catalyst. Finally, condensation of 5-amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,3H)-dione (9) with formic acid gave 1,3,9-trimethy1-3,9-dihydro-purin-2,6 (3H,9H)-di one (10). Necessary 8-bromo-1,3,9-trimethy1-3,9-dihy dropurin-2,6(3H,9H)-dione (11) was obtained in the reaction of compound 10 with N-bromosuccinimide (NBS) in acetonitrile. The procedures shown in the Scheme 3 are general and can be used to prepare analogous 8-bromo 1,3,9-substituted 1H-purine-2,6(3H,9H)-diones.
Date Recue/Date Received 2021-07-07
11 Scheme 3. Preparation of 8-bromo 1H-purine-2,6(3H,9H)-dione 11 (II, wherein R3 is at purine N(9)).

N 2 MeNH2 NO2 I I
0 N 0 ONCI H2SO4 ONCI H20 (:)N NH
I \

H2 N)./NH2 HCO2H
NBS
I I I
Pd/C ONNH

It will be appreciated that in the above transformations it may be necessary or desirable to protect any sensitive groups in the molecule of the compound in question in order to avoid undesirable side reactions.
EXPERIMENTAL PART
The compounds and their preparation of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention.
Hereinafter, "DMF" is defined as N,N-dimethylformamide, "DMAC" is defined as N,N-dimethylacetamide, "NMP" is defined as N-methylpyrrolidone, "DMSO" as dimethyl sulfoxide, "HCl" as hydrochloric acid, õaq. N143" as aqueous ammonia solution, õ"MeCN" as acetonitrile, "DIEA" as diisopropylethylamine, "Et0Ac" as ethyl acetate, "rt" as room temperature.
Intermediate 3.
8-Bromo-1,3,7-trimethy1-1H-purine-2,6(3H,71/)-d lone (3) N IBr To a round-botton flask containing freshly distilled CH2C12 (150 mL) was added caffeine (10.0 g, 0.05 mol) and NBS (17.6 g, 0.10 mol). When the solids had Date Recue/Date Received 2021-07-07
12 dissolved in solvent, water (50 mL) was added and the reaction mixture was stirred for 5 days. Then cold 2 M aq.NaOH (30 mL) was added and the mixture was shaken till decolorization. The organic layer was separated, washed with water (2x200 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (13.5 g, 99%). Ili NMR (CDC13/TMS, 400 MHz) 8 (ppm): 3.41 (s, 3H, CH3), 3.57 (s, 3H, CH3), 3.97 (s, 3H, CH3).
Intermediate 4 8-Bromo-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,71/)-dione (4) I
ONN
To a round-botton flask containing freshly distilled CH2C12 (150 mL) was added pentoxifylline (13.4 g, 0.05 mol) and NBS (17.6 g, 0.10 mol). When the solids had dissolved, water (50 mL) was added and the reaction mixture stirred for 5 days. Then cold 2 M aq. NaOH (30 mL) was added and the mixture was shaken till decolorization.
The organic layer was separated, washed with water (2x200 mL), dried over sodium sulfate, filtered and evaporated to give the title compound (16.95 g, 95%). 11-(CDC13/TMS, 400 MHz) (ppm): 1.61-1.67 (m, 4H), 2.14 (s, 3H), 2.49 (t, 2H), 3.54 (s, 3H), 3.95 (s, 3H), 3.99 (t, 2H).
Intermediate 11.
8-Bromo-1,3,9-trimethy1-1H-purine-2,6(3H,91/)-dione (11).

I
ONN
\
a) 6-Chloro-1,3-dimethylpyrimidine-2,4(1H,31/)-dione (6).
To a suspension of 1,3-dimethylbarbituric acid (7.8 g, 50 mmol) in POC13 (60 mL) was slowly added water (2.5 mL, 0.14 mol) and the reaction mixture was refltixed for 1 h under nitrogen atmosphere. An excess of POC13 was distilled off under reduced presssure and the residue was quenched with 40 mL of ice water. The mixture was Date Recue/Date Received 2021-07-07
13 extracted with chloroform (2x100 mL). The organic phase was dried over anhydrous Na2SO4, evaporated to dryness, and the residue crystallized with ether to give the title compound (8.0 g) as a yellow crystals. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.10 and 3.15 (both s, both 3H), 6.07 (s, 1H).
b) 6-Chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7).
Compound 6 (15 g, 74.5 mmol) was added portionwise to a cooled solution of conc.
H2SO4 (40 mL) . The reaction temperature was maintained below 10 C. Fuming nitric acid (15 mL) was added dropwise to the above reaction mixture and it was stirred for 2 h at the same temperature. The reaction nixture was poured onto the ice cold water (500 mL) and extracted with chloroform (2x260 mL). The combined organic extracts were washed with water (260 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give the title compound (12.0 g) as a yellow solid.

(400 MHz, DMSO-d6) 8 (ppm): 3.07 and 3.26 (both s, both 3H).
c) 1,3-Dimethy1-6-methylamino-5-nitropyrimidine-2,4(1H,3H)-dione (8).
To a stirred solution of 6-chloro-1,3-dimethy1-5-nitropyrimidine-2,4(1H,3H)-dione (7) (11.0 g, 50.1 mmol) in chloroform (90 mL) was added dropwise a solution of 40%
aq.
methylamine (7.76 mL, 100.2 mmol) in dichloromethane (20 mL) under nitrogen atmosphere. After stirring at room temperature for 1 h the reaction mixture was concentrated under reduced pressure. The residue was crystallized from ether to give the title compound (12.5 g) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 2.49, 2.75 and 3.35 (all s, all 3H), 7.74 (br s, 1H).
d) 5-Amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,3H)-dione (9).
To a stirred solution of 1,3-dimethy1-6-methylamino-5-nitropyrimidine-2,4(1H,3H)-dione (8) (2 g, 10 mmol) in wet methanol (140 mL) was added 10% Pd-C (1 g) under hydrogen balloon atmosphere at room temperature. After overnight stirring, the reaction mixture was filtered and the filtrate was concentrated to give the title compound (1.5 g). 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 2.89 (d, 3H), 3.31 (s, 3H), 3.40 (s, 3H), 4.75 (br s, 1H). MS (El) m/z: 185 [Mr.
e) 1,3,9-Trimethy1-1H-purine-2,6(3H,91/)-dione (10).
A mixture of 5-amino-1,3-dimethy1-6-methylamino-pyrimidine-2,4(1H,311)-dione (9) (1.5 g) and formic acid (10 mL) was refh.med for 3 h under nitrogen atmosphere. An excess of formic acid was evaporated under reduce pressure. The residue was extracted with CH2C12, washed with aq. Na2CO3, dried over Na2SO4 and evaporated Date Recue/Date Received 2021-07-07
14 to dryness. The residue was purified by column chromatography (eluent CH2C12 :

Me0H, 10:1) to give the title compound (0.5 g) as a white solid. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.22, 3.68 and 3.93 (all s, all 3H), 7.66 (s, 1H). MS (El) m/z: 195 [M+2]+.
f) 8-Bromo-1,3,9-trimethy1-1H-purine-2,6(3H,9H)-dione (11).
A mixture of 1,3,9-trimethy1-1H-purine-2,6(3H,9H)-dione (10) (1.0 g, 5.15 mmol) and NBS (1.2 g, 6.7 mmol) in dry MeCN (40 mL) was stirred for 3 h at room temperature. Water (30 mL) and CH2C12 (150 mL) was added, the organic phase was separated, dried over Na2SO4 and evaporated to dryness. The residue was purified by column chromatography (CH2C12 : Me0H, 9:1) to give the title compound (0.57 g) as a white solid with m.p. >200 C. 1H NMR (400 MHz, DMSO-d6) 8 (ppm): 3.22, 3.69 and 3.88 (all s, all 3H). MS (El) m/z: 375 [M+21 .
Example 1 8-(3-Hydroxy-3-methylbut-1-yn-l-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione (1-1) OH
I

Method A. To a mixture of PdC12 (113 mg, 0.637 mmol), CuI (242 mg, 1.27 mmol), and triphenylphosphine (333 mg, 1.27 mmol) was added dry NMP or DMF (40 mL).
The reaction mixture was allowed to stir at 40 C for 15 min with simultaneous barbotation with argon. Then a solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione (1.73 g, 6.37 mmol) and 2-methylbut-3-yn-2-ol (0.93 mL, 9.56 mmol) and dry DIEA (3.6 mL) was added and stirring was continued at 50 C
for 24 h. After cooling to rt, the reaction mixture was poured to Et0Ac (300 mL), washed with brine (80 mL) containing aq. NH3 (0.5 mL) and stirred at rt for the additional min. The aqueous phase was separated and the organic phase was washed with brine (3 x 80 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel using a mixture of water (containing 0.1% HC1) - MeCN (5% - 70%) as eluent to 30 give the title compound in 42% yield. mp = 180-182 C. 1H NMR
(CDC13/TMS, 400 MHz) (ppm): 1.63 (s, 6H), 3.36 (s, 3H), 3.51 (s, 3H), 3.52 (br s, 1H), 3.90 (s, 3H).
Date Recue/Date Received 2021-07-07
15 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 28.0, 29.8, 30.8, 32.9, 65.1, 69.6, 102.5, 107.5, 135.0, 147.4, 151.5, 154.6. MS (EI) m/z: 277.2 [M+11 .
Method B. To a mixture of Pd(OAc)2 (100 mg, 0.446 mmol), CuI (169 mg, 0.868 mmol), and triphenylphosphine (233 mg, 0.890 mmol) dry NMP or DMAC (40 mL) was added. Reaction mixture was allowed to stir for 15 min at 40 C with simultaneous barbotation with argon. Then a solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione (1.21 g, 4.46 mmol) and 2-methylbut-3-yn-2-ol (0.65 mL, 6.69 mmol) and dry DIEA (4.0 mL) was added and stirring was continued at 55 C
for 24 h. Compound I-1 (31% yield) was isolated as in Method A.
Method C. To a mixture of Pd(OAc)2 (100 mg, 0.446 mmol), CuI (169 mg, 0.868 mmol), and triphenylphosphine (233 mg, 0.890 mmol) dry NMP (10 mL) was added.
Reaction mixture was allowed to stir for 15 min at 40 C with simultaneous barbotation with argon. Then solution of 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,710-dione (1.21 g, 4.46 mmol) and 2-methylbut-3-yn-2-ol (0.65 mL, 6.69 mmol) and dry DIEA (4.0 mL) in NMP (10 mL) and toluene (20 mL) was added and stirring was continued at 50 C for 24 h. Compound I-1 (72% yield) was isolated as in Method A.
Method D. A vial charged with Pd(PPh3)4 (346 mg, 0.3 mmol), PdC12 (51 mg, 0.3 mmol), Ph3P (157 mg, 0.6 mmol), CuI (58 mg, 0.3 mmol), 8-bromo-1,3,7-trimethy1-1H-purine-2,6(3H,71-1)-dione (4.08 g, 15.0 mmol) and 2-methylbut-3-yn-2-ol (2.05 mL, 21.0 mmol), DIEA (5.0 mL) and ethyl acetate (70 mL) was stirred for 15 min at 40 C with simultaneous barbotation with argon. Then reaction mixture was stirred for additional 2-4 h. After cooling to rt, the reaction mixture was filtered through a silica gel pad and washed with Et0Ac (200 mL). Then solvent was evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel using mixture of water (containing 0.1% aq. HC1) ¨
MeCN (5% - 70%) as eluent to give compound I-1 in 55% yield and 8-[(E)-5-hydroxy-2-(1-hydroxy-1-methylethyl)-5-methylhex-1-en-3-ynyll -1,3 ,7-tri methyl-1H-purine-2,6(3H,7H)-dione as a by-product in 26% yield. By-product: 11-1 NMR
(CDC13/TMS, 400 MHz) (ppm): 1.32 (s, 6H), 1.52 (s, 6H), 3.35 (s, 3H), 3.49 (s, 3H), Date Recue/Date Received 2021-07-07
16 4.03 (s, 3H). 5.13 (hr s, 2H), 6.65 (s, 1H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 28.1, 29.7, 29.9, 31.0, 33.7, 65.3, 70.7, 78.6, 95.9, 107.9, 109.6, 146.5, 147.3, 151.2, 155.0, 156.1.
Example 2 8-((1-Hydroxycyclohexypethyny1)-1,3,7-trimethy1-1H-purine-2,6(3H,71/)-d lone (I-2) H
I

Yield: 49% (Method C), 54% (Method D), 11% (Method B); mp = 194-196 C. 1H
NMR (CDC13/TMS, 400 MHz) (ppm): 1.24-1.33 (m, 1H), 1.48-1.57 (m, 3H), 1.66-1.75 (m, 4H), 1.94-2.02 (m, 2H), 3.30 (hr s, 1H), 3.34 (s, 3H), 3.49 (s, 3H), 3.89 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 22.9, 24.8, 27.9, 29.7, 32.9, 39.2, 68.6, 71.5, 102.0, 107.4, 135.1, 147.3, 151.4, 154.5. MS (EI)m/z: 317.5 1M+11 .
Example 3 8-((1-Aminocyclohexypethyny1)-3,7-dimethyl-11-/-purine-2,6(3H,7H)-dione (I-3) HN )-----"N' H2% ) Yield: 48% (Method D), 43% (Method C), 16% (Method B), 7 % (Method A); mp =
187-189 C. 1H NMR (CDC13/TMS, 400 MHz) g(ppm): 1.20-1.29 (m, 1H), 1.48-1.67 (m, 5H), 1.72-1.77 (m, 2H), 1.81 (br s, 2H), 1.93-1.97 (m, 2H), 3.39 (s, 3H), 3.55 (s, 3H), 3.98 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.2, 25.1, 27.9, 29.7, 33.0, 39.6, 50.4, 70.9, 104.5, 107.6, 135.8, 147.6, 151.5, 154.8. MS (El) m/z:
302.3 1M+11+.
Example 4 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,71f)-dione (I-4) Date Recue/Date Received 2021-07-07
17 I ¨ __ \N¨

O N
Isolated as hydrochloride. Yield: 58% (Method D), 47% (Method C), 4% (Method B);
mp = 197-199 C (dec.) 1H NMR (DMSO-d6, 400 MHz) (ppm): 2.88 (s, 6H), 3.21 (s, 3H), 3.38 (s, 3H), 3.96 (s, 3H), 4.50 (s, 2H). 13C NMR (DMSO-d6, 100.6 MHz) (ppm): 27.6, 29.3, 33.0, 41.6, 45.7, 76.4, 87.1, 107.6, 132.9, 146.8, 150.7, 154Ø MS
(El) m/z: 277.5 [M+11.
Example 5 8-(3-(bis (2-methoxyethyl)amino)p ro p- 1-yn- 1-y1)- 1,3,7-trimethyl- 1H-p urine-2,6(3H,7H)-dione (1-5) I ¨ __ \
\-0\

Yield: 33% (Method D), 30% (Method C), 10% (Method B); foam. 1H NMR
(CDC13/TMS, 400 MHz) g(ppm): 2.79 (t, 4H), 3.31 (s, 6H), 3.34 (s, 3H), 3.48 (t, 4H), 3.51 (s, 3H), 3.82 (s, 2H), 3.96 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm):
27.8, 29.6, 33.0, 44.1, 53.5, 58.7, 70.9, 73.2, 94.1, 107.5, 135.4, 147.5, 151.4, 154.7.
MS (EI)m/z: 364.5 [M+11 .
Example 6 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,71f)-dione (1-6) I ________________________________________ \

Yield: 57% (Method D), 52% (Method C), 8% (Method A); mp = 149-150 C. 1H
NMR (CDC13/TMS, 400 MHz) (ppm): 1.83-1.86 (m, 4H), 2.68-2.72 (m, 4H), 3.39 Date Recue/Date Received 2021-07-07
18 (s, 3H), 3.56 (s, 3H), 3.75 (s, 2H), 4.00 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.8, 27.9, 29.7, 33.1, 43.6, 52.7, 72.6, 94.5, 107.6, 135.4, 147.6, 151.5, 154.8. MS (EI)m/z: 302.3 [M+11+.
Example 7 1,3,7-Trimethy1-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione (1-7) I ¨ __ \

Yield: 35% (Method C), 30% (Method D); mp = 137-138 C. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.40-1.48 (m, 2H), 1.60-1.67 (m, 4H), 2.54-2.60 (m, 4H), 3.39 (s, 3H), 3.55 (s, 3H), 3.60 (s, 2H), 4.00 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 23.6, 25.8, 27.9, 28.0, 29.8, 48.3, 53.4, 73.2, 94.2, 107.6, 135.5, 147.6, 151.5, 154.8. MS (EI) m/z: 316.3 [M+11+.
Example 8 8-(3-(Azepan-l-yl)prop-1-yn-l-y1)-1,3,7-trimethyl-IH-purine-2,6(3H,71/)-dione (1-8) I ________________________________________ \

Yield: 34% (Method C), foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.61-1.64 (m, 4H), 1.70-1.76 (m, 4H), 2.81 (t, 4H), 3.39 (s, 3H), 3.55 (s, 3H), 3.74 (s, 2H), 4.01 (s, 3H). 13C NMR (CDC13/TMS, 100.6 MHz) 8 (ppm): 26.6, 27.9, 28.0, 29.7, 33.1, 48.7, 55.3, 72.9, 93.2, 107.6, 135.4, 147.6, 151.5, 154.8. MS (EI)m/z: 330.3 [M+11 .
Example 9 Date Recue/Date Received 2021-07-07
19 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,71/)-d lone (I-9) NN
=
ONN

Yield: 38% (Method C), mp =188-190 C. 11-1 NMR (CDC13/TMS, 400 MHz) (ppm): 2.64 (t, 4H), 3.40 (s, 3H), 3.56 (s, 3H), 3.64 (s, 2H), 3.76 (t, 4H), 4.01 (s, 3H).
13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 28.0, 29.7, 33.2, 47.8, 52.3, 66.7, 73.7, 93.1, 107.7, 135.2, 147.6, 151.5, 154.8. MS (0) m/z: 318.3 [M+11 .
Example 10 8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (I-10) OH
=
ONN
Yield: 47% (Method D), 44% (Method C); foam. 1H NMR (CDC13/TMS, 400 MHz) c5 (ppm): 1.62-1.66 (m, 4H), 1.65 (s, 6H), 2.12 (s, 3H), 2.48 (t, 2H), 2.72 (hr s, 1H), 3.53 (s, 3H), 3.96 (s, 3H), 3.97 (t, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) g(ppm):
20.9, 27.3, 29.7, 29.9, 30.9, 33.0, 40.9, 43.1, 65.4, 70.0, 102.2, 107.7, 135.1, 147.6, 151.2, 154.6, 208.7. MS (0) inlz: 361.1 [M+11 .
Example 11 8-((1-Hydroxycyclohexypethyny1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (I-11) )N)=_.,_1\1 HO
I ¨
CN
N
Yield: 42% (Method C), mp = 126-128 C. 11-1 NMR (CDC13/TMS, 400 MHz) (ppm): 1.27-1.37 (m, 1H), 1.54-1.79 (m, 7H), 2.02-2.08 (m, 2H), 2.13 (s, 3H), 2.48 (t, 2H), 3.54 (s, 3H), 3.97 (s, 3H), 3.97-4.01 (2H, m). 13C NMR (CDC13/TMS, 100.6 Date Recue/Date Received 2021-07-07 MHz) (ppm): 20.9, 23.0, 24.9, 27.4, 29.7, 29.9, 33.1, 39.3, 40.9, 43.1, 69.0, 72.0, 101.5, 107.8, 135.3, 147.6, 151.2, 154.6, 208.6. MS (El) m/z: 401.6 [M+11 .
Example 12 8-((1-Aminocyclohexypethyny1)-3,7-dimethy1-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione (1-12) )LNN H2N
¨
N N
Yield: 45% (Method C), mp > 200 C. 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm):
1.24-1.34 (m, 1H), 1.61-1.84 (m, 7H), 1.95-2.01 (m, 2H), 2.13 (s, 3H), 2.34-2.37 (m, 2H), 2.48 (t, 2H), 3.39 (s, 3H), 3.49 (s, 3H, 3.93-3.97 (m, 2H), 4.01 (s, 3H), 9.28 (br s, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 20.9, 22.5, 24.1, 27.3, 25.1, 29.7, 29.9, 33.5, 35.9, 41.0, 43.1, 53.6, 75.7, 93.9, 108.0, 133.8, 147.4, 150.9, 154.4, 208.6.
MS (0) m/z: 400.5 [M+11 .
Example 13 8-(3-(Bis(2-methoxyethyDamino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,71/)-dione (1-13) )N
0 N N N¨\
\-0 Yield: 35% (Method C), foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.60-1.65 (m, 4H), 2.10 (s, 3H), 2.47 (t, 2H), 2.34-2.37 (m, 2H), 2.83 (t, 4H), 3.30 (s, 6H), 3.45 (t, 4H), 3.54-3.55 (m, 2H), 3.56 (s, 3H), 3.92 (s, 3H), 3.97 (t, 2H). 13C NMR
(CDC13/TMS, 100.6 MHz) g(ppm): 20.9, 27.4, 29.8, 31.9, 40.7, 43.1, 54.2, 58.8, 63.0, 66.5, 71.0, 76.9, 107.2, 110.3, 143.1, 147.3, 148A, 151.3, 155.1, 208.6. MS
(0) m/z:
448.6 [M+11 .
Example 14 Date Recue/Date Received 2021-07-07
21 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-yDp ro p-1-yn-l-y1)-1H- pu rine-2,6(3H,7H)-dione (1-14) I
0 N.--1\1 Isolated as hydrochloride. Yield: 41%, foam. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.61-1.70 (m, 4H), 1.82-1.86 (m, 4H), 2.13 (s, 3H), 2.49 (t, 2H), 2.64-2.68 (m, 4H), 3.48 (d, 2H), 3.58 (s, 3H), 3.93 (s, 3H), 4.01 (t, 2H), 6.78 (hr s, 1H).

(CDC13/TMS, 100.6 MHz) g(ppm): 20.8, 23.9, 27.3, 29.6, 29.9, 33.6, 40.9, 43.0, 43.3, 52.7, 77.6, 85.1, 108.4, 133.0, 147.4, 151.0, 154.5. 208.5. MS (EI)m/z: 386.3 [M+11 .
Example 15 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione (1-15) ______________________________________________ \N

Yield: 39% (Method C), mp = 182-184 C. 1H NMR (CDC13/TMS, 400 MHz) (ppm): 1.34-1.48 (m, 1H), 1.58-1.66 (m, 4H), 1.90-1.93 (m, 3H), 2.11 (s, 3H), 2.21-2.29 (m, 2H), 2.47 (t, 2H), 2.94-2.97 (m, 2H), 3.51 (s, 3H), 3.60-3.63 (m, 2H), 3.97 (t, 2H), 4.07 (s, 3H), 4.22 (s, 2H). 13C NMR (CDC13/TMS, 100.6 MHz) (ppm): 20.8, 21.5, 22.7, 27.3, 29.6, 29.9, 33.7, 40.9, 43.0, 46.7, 52.6, 78.7, 84.6, 108.5, 133.1, 147.5, 151.0, 154.5, 208.5. MS (EI)in/z: 400.2 [M+11 .
Example 16 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione (1-16) NN

Date Recue/Date Received 2021-07-07
22 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm): Yield: 36% (Method C). 1H NMR
(CDC13/TMS, 400 MHz) (ppm): 3.43 (s, 3H), 3.61 (s, 3H), 4.10 (s, 3H), 7.39-7.46 (m, 3H), 7.61-7.63 (m, 2H). MS (EI) m/z: 295.5 [Mr Example 17 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,911)-dione (I-17) \
Isolated as hydrochloride. 1H NMR (DMSO-d6, 400 MHz) 8 (ppm): 1.86-1.99 (m, 4H), 3.07-3.20 (m, 4H), 3.25 (s, 3H), 3.72 (s, 3H), 3.93 (s, 3H), 4.35 (s, 2H). MS (El) m/z: 302.1 [Mr Example 18 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione (I-18) _________________________________________ ( I \
Yield: 75% (Method C), mp > 200 C. 1H NMR (CDC13/TMS, 400 MHz) 8 (ppm):
3.42 (s, 3H), 3.80 (s, 3H), 4.06 (s, 3H), 7.35-7.42 (m, 3H), 7.53-7.55 (m, 2H).
13C NMR (DMSO-d6, 100.6 MHz) g (ppm): 28.1, 31.0, 33.8, 78.1, 93.6, 116.6, 120.1, 128.9, 129.9, 131.2, 131.6, 140.0, 150.8, 156.1. MS (EI) m/z: 295.3 [Mr.
ANTIPROLIFERATIVE ACTIVITY
Anticancer activity of 8-ethynylxanthines was tested on monolayer tumor cell lines:
MDA-MB-435s (human melanoma), H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma). The borderline concentration, relevant to the highest tolerated dose, was determined for each Date Recue/Date Received 2021-07-07
23 compound using the NIH 3T3 (Mouse Swiss Albino embryo fibroblasts) cell line.
The basal cytotoxicity was used to predict starting doses for in vivo acute oral LD50 values in rodent. The results of these experiments are summarized in Table 1.
Caffeine, Proxyfeine, Pentoxifylline and Temodar were used as references. Caffeine and Pentoxifylline exhibit no cytotoxic effect on all studied cell lines. Despite the fact that Temodar is widely used drug for brain cancer prevention, in vitro results showed more than a modest activity on studied tumor cell lines (IC50=298 [IM on SH-neuroblastoma and IC50=31 [iM on U937 lymphoma cell lines). Cancer cells are more sensitive to Proxyfeine (IC50=96-283 [iM). Surprisingly, 8-ethynylcaffeines have an extended ability to suppress cancer cell growth. Thus, caffeine derivatives 1-showed high in vitro antiproliferative effect against majority of cancer cells, moreover, these compounds are active against brain tumors (IC50=8.2 11.5 [iM on SH-SY5Y
and C6 cell lines). It should be noted that caffeine 1-3 selectively inhibits lymphoma U937 cell growth (IC50=5.1 HM), and derivative 1-6 ¨ estrogen-positive human breast adenocarcinoma MCF-7 (IC50=5.7 [iM). In a series of pentoxifylline derivatives 15 piperidylmethyl derivative 1-15 showed high cytotoxicity against studied cancer cells, especially, on lymphoma U937 (IC50=4.7 M) and glioma C6 (IC50=7.1 [iM).
In vitro cytotoxicity assay Monolayer tumor cell line: MDA-MB-435s (human melanoma), H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma), and normal cell line NIH 3T3 (mouse fibroblasts) were cultured in standard medium DMEM (Dulbecco's modified Eagle's medium) containing 1% non-essential amino-acids, 2 mM glutamine and supplemented with 10% fetal bovine serum (FBS, Sigma) ("Sigma"). All cells obtained from the American Type Culture Collection.
About 2-10.104 cells/mL (depending on line nature) were placed in 96-well plates immediately after compounds were added to the wells. The control cells without test compounds were cultured on separate plate. The plates were incubated for 72 h, C, 5% CO2. The number of surviving cells was determined using 344,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolinium bromide (MTT). MTT-test: after incubating with preparations culture medium was removed and 200 [it of fresh Date Recue/Date Received 2021-07-07
24 medium with 10 mM HEPES was added in each well of the plate, then 20 [it of MTT (2 mg/mL in HBSS) was added. After incubation (3 h., 37 C, 5%CO2) the medium with MTT was removed and 200 [it of DMSO and 25 [it of glycine buffer (pH 10.5) were added at once to each sample. The samples were tested at 540 nm on Anthos HT II photometer.
Basal toxicity test Compounds were tested on NIH 3T3 (normal mouse fibroblasts, "ATCC") cell line according the basal toxicity test (INVITOX Protocol No 64, 1992) and non-toxic compounds were selected. 9,000 NIH 3T3 cells/well were placed into 96-well plates for 24 h and then exposed to the test compound over a range of eight concentration (1-1000 ng/mL) for 24 h. Upon that, the cells were incubated with the neutral red dye for 4 h and then OD was determined at 540 nm. Alternative LD50 values (LD50 value is the amount of the drug that is taken to kill 50% of the test animals) was calculated according to the formula: log (LD50 [mmol/kg] = 0.435 x log (IC50 Immo1/11) =
0.625.
The IC50 values were calculated using the program Graph Pad 5 Prism 3Ø
Date Recue/Date Received 2021-07-07 o o) (T
x CD
K-) c a) 0 Table 1. In vitro cytotoxicity caused by 8-ethynylxanthines was tested on monolayer tumor cell lines: MDA-MB-435s (human melanoma), m .6 x H9C2 (rat embrio cardiomyoblast), MCF-7 (human breast adenocarcinoma, estrogen-positive), HepG2 (human hepatocellular carcinoma), SH-m m . SY5Y (human neuroblastoma), C6 (rat glioma), U937 (human histiocytic leukemia), and A549 (human lung carcinoma).
m 0.
N., N., 0 MDA-MB-435s 119C2 MCF-7 HepG2 SH-SY5Y C6 -.-, 0 Compound -.., ICso ICso ICso ICso IC50 IC50 IC50 IC50 1_,D50, mg/kg Caffeine * * * * * *
* * 1670 Proxyfeine 283 * 135 * 111 96 97 * 1891 Pentoxifylline * * * * * *
* * >2000 Temodar 515 * * * 298 *
31 * >2000 t.) I-1 119 141 * * 83 261 79 239 1116 t.it 1-2 * * * * * 187 95 * 1329 5.1 52 347 9.2 42 873 1-5 * * * * * *
* * 1924 1-6 8.6 75 5.7 17 8.6 11.5 26 8.6 262 1-7 14 68 14 60 14 8.5 5.7 17 383 1-8 8.2 8.2 8.2 13.7 8.2 8.2 5.5 8.2 287 1-9 * * * * * *
124 * 1676 1-10 * 22 169 86 105 277 I-11 * * 259 * 116 183 o o) (T
x CD
K-) c a) o 1-12 80 46 73 96 64 sm g 1-14 7.3 9.8 4.9 12 4.9 17 12 7.3 253 x m m 1-15 19 52 11.8 26 9.5 7.1 4.7 11.8 698 m 0.

13.6 85 648 r..) r..) 1-17 * * * * 193 *
151 * 1733 -.-, -.., aIC50 - Concentration (pM) providing 50% cell killing effect (MTT).
t\.) ca,

Claims (12)

27
1. A compound selected from those of Formula I:

R1 Nv R3 ¨ ______________________________________________ R4 ON
wherein R1 represents hydrogen, Cl_4alkyl, hydroxy-C2_4a1ky1, Cl_3alkoxy-C2_4alkyl, Ci-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(Ci_3alkyl)amino-C2_4alkyl;
R2 represents C1-4alkyl, hydroxy-C2-4alkyl, Ci_4alkylcarbonyl-C1-4alkyl, Ci-3alkoxy-C2-4alkyl, C1-3alkyl(C1-3alkyl)amino-C2-4alkyl or halo-C2_4alkyl;
R3 represents Ci_4a1ky1, allyl or Ci_3a1koxy-C2_4a1ky1;
R4 represents Ci_4a1ky1, hydroxy-C1_4a1ky1, Ci_3a1koxy-C1-4alkyl, amino-C1_4alkyl, 1-hydroxy-di-(Ci -3 alkyl)methyl, 1-amino-di-(C1_3alkyOmethyl, 1-hydroxy-cyclo-6alky1, 1-amino-cyclo-C3_6alkyl, 1-(hydroxy-C1-3alkyl)-cyc1oC3-6alkyl, Ci-3alkylamino-C1-3a1ky1, C1_3alkyl(C1_3alkyl)amino-C1_3alkyl, di-(C1_3alkoxy-C2_4a1ky1)-amino-C1-3alkyl, heterocyclyl-C1_3alkyl, aryl or heteroaryl;
with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then Ri is not a hydrogen;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and Date Recue/Date Received 2021-07-07 with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocyclyl is one of azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C 1-4 al koxy carbonyl, N-C 1-4alkylaminocarbonyl, N,N-di-(Cl_3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI_ allyl, C2_4a1kyny1, C1_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6a1koxy, hydroxy-Cl_4alkyl, Cl_3a1koxy-C1_4alky1, C1-3 alkoxy-C2_4a1koxy, di-(Ci-3 alkyl)amino, di-(C1_3alky1)amino-C1_3 alkyl, di-(C
1_3 alkyl)amino-C2_4alkoxy, Cl_4alkylsulfonylamino and Ci-4a1ky1-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1_4alk0xy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alk0xy, C1-3 alkoxy-C1_4alkyl, cyclo-C3_6alkylamino and di-(C1_3alkyl)amino;
its optical isomers, and pharmaceutically acceptable acid addition salts and hydrates and solvates thereof with the proviso that 8-(3-hydroxyprop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione is excluded.
2. The compound as claimed in Claim 1, wherein R3 is at purine N(7) atom.
3. The compound as claimed in Claim 1, wherein R3 is at purine N(9) atom.
4. The compound as claimed in any one of Claims 1, 2 and 3, wherein R4 represents hydroxy-Ci_4alkyl, amino-C1_4alky1, 1-hydroxy-di-(C1_3alkyl)methyl, 1 -amino-di-(C 1-3 al kyl)methyl, 1 -hy droxy-cy cl o-C3_6 alkyl, 1 -amino-cy cl o-C3-Date Recue/Date Received 2021-07-07 6alkyl, 1-(hydroxy-Cl_3alkyl)-cyc1oC3_6a1ky1, C1-3alkyl(C1-3alkyl)amino-C1-3alkyl, di-(C1_3alkoxy-C2_4alkyl)-amino-Ci_3alkyl, heterocyclyl-C1-3alkyl or aryl.
5. The compound as claimed in Claim 4, wherein R2 and R3 each independently represent Ci_4a1ky1 or C1-3alkoxy-C2-4alkyl with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then RI is not a hydrogen.
6. The compound as claimed in Claim 5, wherein R2 and R3 each represent methyl.
7. The compound as claimed in any one of Claims 1 to 6, wherein R1 represents methyl or 5-oxohexyl.
8. The compound as claimed in Claim 1, which is selected from:
8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexyl)ethyny1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(Dimethylamino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 8-(3-(bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(pyrrolidin-1-y0prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-(piperidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-(Azepan-1-yl)prop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(3-morpholinoprop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 8-(3-Hydroxy-3-methylbut-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Hydroxycyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 8-((1-Aminocyclohexyl)ethyny1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, Date Recue/Date Received 2021-07-07 8-(3-(Bis(2-methoxyethyl)amino)prop-1-yn-1-y1)-3,7-dimethyl-1-(5-oxohexyl)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(pyrrolidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 3,7-Dimethy1-1-(5-oxohexyl)-8-(3-(piperidin-1-y1)prop-1-yn-1-y1)-1H-purine-2,6(3H,7H)-dione, 1,3,7-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,7H)-dione, 1,3,9-Trimethy1-8-(3-(pyrrolidin-1-yl)prop-1-yn-1-y1)-1H-purine-2,6(3H,9H)-dione, and 1,3,9-Trimethy1-8-(phenylethyny1)-1H-purine-2,6(3H,9H)-dione and optical isomers, and pharmaceutically-acceptable acid addition salts, hydrates, and solvates thereof
9. The compound as claimed in any one of Claims 1 to 8 for use in the treatment or prevention of melanoma, breast adenocarcinoma, hepatocellular carcinoma, neuroblastoma, glioma, lymphoma, or lung cancer.
10. A process for the synthesis of a compound selected from those of Formula I:

R1 it N/R3 -W
j l ___________________________________ = R4 ONN

wherein R1 represents hydrogen, Cl_4alkyl, hydroxy-C2_4alky1, C1-3alkoxy-C2-4alkyl, Ci-3alkylcarbonyl-C1_4alkyl or C1_3alkyl(C1_3alkyl)amino-C2_4alkyl;
R2 represents C1_4alkyl, hydroxy-C2-4.a1ky1, C1_4alkylcarbonyl-C1_4alkyl, C1_3alkoxy-C2-4alkyl, C1-3alkyl(C1-3alkyl)amino-C2-4alkyl or halo-C2_4a1ky1;
R3 represents C1_4alkyl, ally1 or Ci_3alkoxy-C2_4alkyl;
Date Recue/Date Received 2021-07-07 R4 represents Cl_4alkyl, hydroxy-C1-4alkyl, C1_3alkoxy-C1_4alkyl, amino-C1-4alkyl, 1-hy droxy-di-(C _3 alkyl)methyl, 1 -amino-di-(Ci_3 kyl)methy I, 1 -hy droxy-cy cl o-C3-6 alkyl, 1-amino-cyclo-C3_6a1ky1, 1 -(hy droxy-C 1_3alkyl)-cycloC3_6 alkyl, C 1-heterocyclyl-Cl_3alkyl, aryl or heteroaryl;
with the proviso that if R2 is ethyl, R3 is methyl and R4 is 1-hydroxy-ethyl, then R1 is not a hydrogen;
with the proviso that if substituent R3 is at purine N(7) atom the dotted line between N(7) and C(8) represents no bond, and the dotted line between C(8) and N(9) represents chemical bond;
and with the proviso that if substituent R3 is at purine N(9) atom the dotted line between N(7) and C(8) represents chemical bond, and the dotted line between C(8) and N(9) represents no bond;
wherein the term "heterocycly1" represents saturated 4-7 membered heterocycle containing one or two heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heterocycly1 is one of azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuryl, morpholinyl, thiomorpholinyl and piperazinyl;
the term "aryl" represents phenyl or phenyl substituted by one or more substituents selected independently from halogen, cyano, C 1-4 al koxy carbonyl. N-C 1-4alkylaminocarbonyl, N,N-di-(Cl_3alkyl)aminocarbonyl, CH2OH, trifluoromethyl, CI_ 4alky1, allyl, C2_4alkynyl, Ci_4alkoxy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alkoxy, hydroxy-Ci_4alkyl, Ci_3alkoxy-C1_4alky1, Ci_3alkoxy-C2_4alkoxy, 3 alkyl)amino, di-(Ci_3alkyl)amino-C 1-3 alkyl, di-(C1-3alkyl)amino-C2_4alkoxy, Ci_4alkylsulfonylamino and C1-4alky1-aminosulfonyl;
the term "heteroaryl" represents an aromatic 5 or 6 membered ring comprising one to three heteroatoms selected from oxygen, sulfur and nitrogen, wherein the heteroaryl is unsubstituted or is substituted by one or more substituents selected independently from halogen, cyano, trifluoromethyl, C1_4alkyl, C1_4alk0xy, difluoromethoxy, trifluoromethoxy, cyclo-C3_6alk0xy, Ci_3alkoxy-C1_4alkyl, cyclo-C3_6alkylamino and di-(C1_3alkyl)amino;
Date Recue/Date Received 2021-07-07 and its optical isomers, and pharmaceutically acceptable acid and base addition salts and hydrates and solvates thereof with the proviso that 8-(3-hydroxyprop-1-yn-1-y1)-1,3,7-trimethy1-1H-purine-2,6(3H,7H)-dione is excluded;
comprising reaction of a compound of Formula II:
o ' C)NN

with a compound of Formula III:
¨ ____________________________________ R4 in the presence of base in an appropriate solvent, in the presence of CuI and palladium catalyst, or palladium catalyst generated in situ, to yield a compound of Formula I, which is convertible into an optical isomer, pharmaceutically-acceptable salt, hydrate or solvate.
1 1. The process of claim 10, wherein the solvent is selected from diisopropylethylamine (DIEA) in 2,5-dimethylfuran (DMF), N-methy1-2-pyrrolidone (NMP), dimethylacetamide (DMAC) and ethyl acetate (Et0Ac).
12. The process of claim 10 or 1 1, wherein the palladium catalyst is Pd(PPh3)4.
Date Recue/Date Received 2021-07-07
CA2989161A 2015-03-27 2015-03-27 Ethynylxanthines, preparation and use for cancer treatment Active CA2989161C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/LV2015/000001 WO2016159745A1 (en) 2015-03-27 2015-03-27 Ethynylxanthines, preparation and use for cancer treatment

Publications (2)

Publication Number Publication Date
CA2989161A1 CA2989161A1 (en) 2016-10-06
CA2989161C true CA2989161C (en) 2022-03-01

Family

ID=52815227

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989161A Active CA2989161C (en) 2015-03-27 2015-03-27 Ethynylxanthines, preparation and use for cancer treatment

Country Status (3)

Country Link
CA (1) CA2989161C (en)
GB (1) GB2553684B (en)
WO (1) WO2016159745A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2166948C1 (en) 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Method for treating gliomae aggravated with epileptic syndrome
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
EP2190434B1 (en) * 2007-08-17 2019-04-17 Boehringer Ingelheim International GmbH Purin derivatives for use in the treatment of fap-related diseases
WO2011005871A1 (en) * 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
SI2970303T1 (en) 2013-03-15 2017-08-31 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof

Also Published As

Publication number Publication date
WO2016159745A1 (en) 2016-10-06
GB2553684A (en) 2018-03-14
CA2989161A1 (en) 2016-10-06
GB2553684B (en) 2020-06-03
GB2553684A8 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
CA2698018C (en) Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof
TW201718592A (en) Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
KR20180042368A (en) A condensed pyrimidine compound or a salt thereof
CN104169283A (en) Fused tetra or penta-cyclic pyridophthalazinones as PARP inhibitors
KR20060120393A (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
Wang et al. Synthesis and anticancer activity evaluation of a series of [1, 2, 4] triazolo [1, 5-a] pyridinylpyridines in vitro and in vivo
CN101248050A (en) Organic compounds
JP2008546653A (en) N2-quinoline or isoquinoline substituted purine derivatives, process for producing the same and uses thereof
CA2604284A1 (en) Protein kinase inhibitors
CN110167941A (en) Substituted fused heteroaryl compounds are as kinase inhibitor and its application
JP2022518552A (en) PDE9 inhibitor and its uses
JPS6225670B2 (en)
KR20200078610A (en) Amino-substituted nitrogen-containing condensed-ring compounds and preparation methods and uses thereof
JP2023145547A (en) Cd73 inhibitor, preparation method therefor and application thereof
AU2016223683B8 (en) Derivatives of 2-aminopyridine as adenosine a2b receptor antagonists and ligands of the melatonin mt3 receptors
CN108218874B (en) Phosphodiesterase inhibitor and application thereof
JP2015533778A (en) Novel phenyl-pyridine / pyrazine amide for the treatment of cancer
CA2989161C (en) Ethynylxanthines, preparation and use for cancer treatment
ES2896938T3 (en) GSK-3 inhibitors
Guillonneau et al. Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues
WO2022143576A1 (en) Pyrazoloquinazoline compound, and preparation method therefor and use thereof
WO2022007841A1 (en) Egfr inhibitor, preparation method therefor, and pharmaceutical application thereof
CA3135449A1 (en) Triazolopyrimidines based on thymine nucleobase and methods for producing them
EP3098222B1 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof
WO2016159747A1 (en) Ethynylxanthines, preparation and use as calcium ion channel modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200319